Jeff P. Sharman

机构：Willamette Valley Cancer Institute and Research Center · ORCID：0000-0001-5611-6115

发表论文 447 篇 · 总被引 16231 次 · h-index 47

代表论文

• Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor–Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321) (2025 · Journal of Clinical Oncology · 被引 39)
• Five-Year Outcomes of the POLARIX Study Comparing Pola-R-CHP and R-CHOP in Patients With Diffuse Large B-Cell Lymphoma (2025 · Journal of Clinical Oncology · 被引 34)
• Fixed treatment duration subcutaneous mosunetuzumab monotherapy in elderly/unfit patients with previously untreated diffuse large B-cell lymphoma: Interim results from the Phase II MorningSun study (2025 · Blood · 被引 6)
• PROs vs clinician-reported adverse events in a large clinical trial: findings from the phase 3 POLARIX study (2025 · Blood · 被引 3)
• Fixed-duration subcutaneous (SC) mosunetuzumab, with maintenance therapy, in patients (pts) with previously untreated high-tumor burden follicular lymphoma (HTB FL): Longer follow-up and exploratory circulating tumor (ct)DNA analysis of the Phase II MorningSun study (2025 · Blood · 被引 2)
• Erratum: Five-Year Outcomes of the POLARIX Study Comparing Pola-R-CHP and R-CHOP in Patients With Diffuse Large B-Cell Lymphoma (2025 · Journal of Clinical Oncology · 被引 1)